Department of Medicine, Université de Montréal, Montréal, QC, Canada.
Department of Medicine, McGill University, Montréal, QC, Canada.
J Cutan Med Surg. 2024 Nov-Dec;28(6):572-576. doi: 10.1177/12034754241274356. Epub 2024 Aug 27.
Xanthoma disseminatum (XD) is a rare normolipidemic mucocutaneous xanthomatosis within the spectrum of cutaneous non-Langerhans histiocytosis. Managing XD poses substantial challenges, with limited available data. This study aims to comprehensively evaluate existing literature on clinical features of XD and treatment outcomes. A systematic search of MEDLINE, Embase, and PubMed was performed, using "xanthoma disseminatum" and "Montgomery syndrome" as search terms, without restrictions. Screening was performed in duplicate by 2 reviewers. One hundred fifty-one studies met the inclusion criteria, yielding 166 cases of XD (106 females, 60 males), mean age at diagnosis 35.3 years (range: 9 months-87 years). XD typically presented as yellow-to-brown coalescing papules/plaques and nodules. Distribution affects mainly the face (n = 116/166), flexures (n = 45/166), trunk (n = 65/166), and genitalia/inguinal areas (n = 63/166). Most cases (99.4%; n = 165/166) exhibited extracutaneous manifestations, including the pituitary gland and the oropharynx. Treatment options rendered low complete response rates (CRRs). Treatments with reported outcomes included surgical resection (n = 17/99), systemic steroids (n = 40/99), immunosuppressants/immunomodulators (n = 73/99), energy-based devices (n = 7/99), lipid-lowering agents (n = 24/99), cryotherapy (n = 6/99), lasers (n = 10/99), topical steroids (n = 6/99), oral retinoids (n = 2/99), and radiotherapy (n = 5/99), with CCRs of 23.5% (n = 4/17), 5.0% (n = 2/40), 9.6% (n = 7/73), 14.3% (n = 1/7), 4.2% (n = 1/24), 16.7% (n = 1/6), 10.0% (n = 1/10), 0% (n = 0/6), 0% (n = 0/2), and 0% (n = 0/5), respectively. The most promising therapy is cladribine, with the highest CRR of 27.1% (n = 6/22) and the lowest no response rate (9.1%; n = 2/22) of all reported treatments. This review confirms the high prevalence of systemic manifestations in XD. Treatment options vary widely; thus, further research is needed to establish management strategies for this challenging condition.
播散性黄色瘤病 (XD) 是一种罕见的非朗格汉斯组织细胞谱系皮肤组织细胞增生症中的正常脂质皮肤黏膜黄瘤病。XD 的管理具有挑战性,因为现有数据有限。本研究旨在全面评估 XD 的临床特征和治疗结果的现有文献。通过使用“xanthoma disseminatum”和“Montgomery syndrome”作为检索词,对 MEDLINE、Embase 和 PubMed 进行了系统检索,没有任何限制。由 2 名审查员进行重复筛选。151 项研究符合纳入标准,共纳入 166 例 XD 患者(女性 106 例,男性 60 例),诊断时的平均年龄为 35.3 岁(范围:9 个月至 87 岁)。XD 通常表现为黄色至棕色融合的丘疹/斑块和结节。分布主要影响面部(n = 116/166)、弯曲处(n = 45/166)、躯干(n = 65/166)和生殖器/腹股沟区(n = 63/166)。大多数病例(99.4%;n = 165/166)存在皮肤外表现,包括垂体和口咽。治疗方法的完全缓解率(CRR)较低。具有报告结果的治疗方法包括手术切除(n = 17/99)、全身类固醇(n = 40/99)、免疫抑制剂/免疫调节剂(n = 73/99)、能量基设备(n = 7/99)、降脂药(n = 24/99)、冷冻疗法(n = 6/99)、激光(n = 10/99)、局部类固醇(n = 6/99)、口服类视黄醇(n = 2/99)和放射疗法(n = 5/99),CRR 分别为 23.5%(n = 4/17)、5.0%(n = 2/40)、9.6%(n = 7/73)、14.3%(n = 1/7)、4.2%(n = 1/24)、16.7%(n = 1/6)、10.0%(n = 1/10)、0%(n = 0/6)、0%(n = 0/2)和 0%(n = 0/5)。最有前途的治疗方法是克拉屈滨,其 CRR 最高为 27.1%(n = 6/22),所有报告的治疗方法中无反应率最低(9.1%;n = 2/22)。本综述证实 XD 存在很高的全身表现发生率。治疗方法多种多样;因此,需要进一步研究以建立这种具有挑战性疾病的管理策略。